Oncotype DX AR-V7 NUCLEUS DETECT

Is Your Patient Eligible?

An estimated 50,000 mCRPC patients each year could benefit from knowing their AR-V7 status

It’s estimated that about 50,000 metastatic castration-resistant prostate cancer (mCRPC) patients each year could benefit from knowing their AR-V7 status prior to selecting treatment. Patients who are resistant to androgen receptor (AR)-targeted therapies, such as abiraterone or enzalutamide, often respond to taxane chemotherapy.1,2,3 The Oncotype DX AR-V7 Nucleus Detect test can help you confidently choose the therapy that will help offer your patients the opportunity for longer overall survival.

Eligibility criteria

The AR-V7 Nucleus Detect assay is ideal for patients who:

  • Have confirmed mCRPC
  • Have received and failed AR-targeted therapy
  • Are considering additional AR-targeted therapies

When to order the AR-V7 Nucleus Detect test

Ordering the AR-V7 Nucleus Detect test is appropriate for patients with mCRPC whenever you’re considering AR-targeted therapy for a patient.

Why order the test before ordering AR-targeted therapies

Although AR-targeted therapies are a breakthrough in mCRPC treatment, it’s important to remember that some patients never respond to AR-targeted therapies and many patients who initially respond to AR-targeted therapies develop acquired resistance to them over time.4

The percentage of patients who are nuclear AR-V7+ (an absolute indicator that a patient will not respond to AR-targeted therapies) increases with each exposure to AR-targeted therapies5:

  • Roughly 1 in 5 patients (18%) are nuclear AR-V7+ after receiving abiraterone or enzalutamide.
  • Roughly 1 in 3 patients (31%) are nuclear AR-V7+ after receiving two rounds of AR-targeted therapy.

The percentage of mCRPC patients with the AR splice variant (AR-V7+) increased with continued exposure to AR-targeted therapies5

AR Resistance Graph
Cross-sectional cohort study. Blood samples were collected from 161 patients with mCRPC and tested for the presence of AR-V7.

REFERENCES

1. Antonarakis et al. N Engl J Med. 2014.
2. Scher et al. Eur Urol. 2016.
3. Antonarakis et al. JAMA Oncol. 2015.
4. Antonarakis et al. Expert Rev Anticancer Ther. 2015.
5. Scher et al. JAMA Oncol. 2016.

 

Do You Have a Question?

Contact Us
Physician Login

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™